Evidence map›Paper›PMID 32795465›Full record

ArticleHuman pathology2020

Chromosome 3p loss of heterozygosity and reduced expression of H3K36me3 correlate with longer relapse-free survival in sacral conventional chordoma.

Guo Gord Zhu, Daniel Ramirez, Wen Chen, Chao Lu, Lu Wang, Denise Frosina, Achim Jungbluth, Peter Ntiamoah, Khedoudja Nafa, Patrick J Boland and 1 more

Open access · greenAbstract read
In one paragraph

Article in Human pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Guo Gord ZhuDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA; Department of Pathology, Cooper University Hospital, Cooper Medical School of Rowan University, Camden, NJ, 08003, USA.
Daniel RamirezDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA; Department of Pathology, Northwell Health, Great Neck, NY, 11021, USA.
Wen ChenDepartment of Pathology, Washington DC VA Medical Center, Washington, DC, 20422, USA.
Chao LuDepartment of Genetics & Development, Columbia University Medical Center, New York, NY, 10032, USA.
Lu WangDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
Denise FrosinaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Achim JungbluthDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Peter NtiamoahDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Khedoudja NafaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Patrick J BolandOrthopaedic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Meera R HameedDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. Electronic address: hameedm@mskcc.org.
Memorial Sloan Kettering Cancer Center · USColumbia University Irving Medical Center · USSt. Jude Children's Research Hospital · USWashington DC VA Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Conventional chordoma is a rare slow-growing malignant tumor of notochordal origin primarily arising at the base of the skull and sacrococcygeal bones. Chordoma may arise from its benign counterpart, benign notochordal cell tumors, and can also undergo dedifferentiation progressing into dedifferentiated chordoma. No study has directly compared the genomic alterations among these tumors comprising a morphologic continuum. Our prior study identified frequent chromosome 3p loss of heterozygosity and minimal deleted regions on chromosome 3 encompassing SETD2, encoding a histone methyltransferase involved in histone H3 lysine 36 trimethylation (H3K36me3). In the present study, we expanded our study to include 65 sacral conventional chordoma cases, 3 benign notochordal cell tumor cases, and 2 dedifferentiated chordoma cases using single nucleotide polymorphism (SNP) array, targeted next-generation sequencing analysis, and immunohistochemistry. We performed immunohistochemical analysis of histone, H3K36me3, and investigated whether there is any association between the clinical behavior and recurrent chromosome or aneuploidy or H3K36me3 protein expression. We found that there is increased genomic instability from benign notochordal cell tumor to conventional chordoma to dedifferentiated chordoma. The highly recurrent genomic aberration, chromosome 3p loss of heterozygosity (occurred in 70% of conventional chordomas), is correlated with longer relapse-free survival, but not with overall survival or metastasis-free survival in sacral chordoma. Chordomas demonstrate variable patterns and levels of H3K36me3 expression, and reduced expression of H3K36me3 showed marginally significant correlation with longer relapse-free survival. Copy number alterations in the genes encoding the H3K36me3 methylation transferase complex and demethylase may account for the altered H3K36me3 expression levels.

Indexed as

Chromosomes, Human, Pair 3DNA MethylationLoss of HeterozygosityAdultAgedAged, 80 and overBiomarkers, TumorChordomaDisease ProgressionFemaleHistone-Lysine N-MethyltransferaseHumansMaleMiddle AgedNeoplasm Recurrence, LocalPolymorphism, Single NucleotideBiomarkers, TumorHistone-Lysine N-MethyltransferaseSETD2 protein, humanChordomaEpigeneticsGeneticsH3K36me3Relapse-free survival

Identifiers

PMID32795465
PMCPMC8366418
OpenAlexW3048467195

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.